ASCO 2016: Real world skeletal related events (SREs) associated with oral treatments in patients with metastatic castration-resistant prostate cancer (mCRPC).


Bone metastasis occurs in a majority of patients with advanced prostate cancer and represents a clinically significant issue in the management of these patients. Patients with bone metastases are at increased risk for skeletal complications, including pathologic fracture, spinal cord compression, and radiation or surgery to the bone, collectively termed skeletal-related events (SREs).1 SREs are associated with not only substantial morbidity but also greater mortality, increased pain, decreased quality of life, and increased treatment costs.2-6

ASCO 2016: A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer – results of SPCG12.

Goran Ahlgren, PhD.  discussed the initial results from the phase III prospective randomized trial sponsored by the Scandinavian Prostate Cancer Group, SPCG12. The purpose of this study was to use adjuvant chemotherapy to prolong the survival of men with high risk prostate cancer after radical prostatectomy.  The authors hypothesized that, similar to other solid tumors, adjuvant chemotherapy may prolong survival in the adjuvant setting as it does in the metastatic setting.

ASCO 2016: Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).

Linda Patrick-Miller, Ph.D, presented the quality of life analysis from the CHAARTED trial (Chemohormonal androgen ablation randomized trial in prostate cancer (E3805)) including men with metastatic hormone sensitive prostate cancer. A secondary endpoint of the study was to determine whether an increase in disease control with androgen deprivation therapy (ADT) plus docetaxel was associated with a change in quality of life. The study included patient reported outcomes on overall quality of life, disease related symptoms, and treatment related symptoms.

ASCO 2016: Atezolizumab: Potential New Standard of Care in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer: Results From IMvigor210 - An Interview.


Advanced sequencing methods have led to the identification of numerous molecular markers in urothelial carcinoma that can be exploited with targeted therapies. 

In May 2016, cancer immunotherapy, atezolizumab (TECENTRIQ™) received accelerated FDA approval for the treatment of individuals with previously treated or locally advanced or metastatic urothelial cancer (mUC). This approval represented the first of its kind for this cancer in decades.

Here, Arjun V. Balar, MD, Director of Genitourinary Medical Oncology, NYU Perlmutter Cancer Center, speaks to Urotoday about the meaning of this advance in treatment and about important findings he reported for first-line treatment of advanced or metastatic urothelial cancer at the 2016 ASCO Annual Meeting, held June 3-7, in Chicago, IL.